Phosphate handling by end-stage kidneys and benefits of residual renal function on phosphate removal in patients on haemodialysis

Nephrology

Volumn 18, Issue 4, 2013, Pages 285-291

  Iwasawa, Hideaki ^a   Nakao, Toshiyuki ^a   Matsumoto, Hiroshi ^a   Okada, Tomonari ^a   Nagaoka, Yume ^a   Wada, Toshikazu ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

end stage kidney disease; haemodialysis; phosphate; residual renal function

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM CARBONATE; CREATININE; FIBROBLAST GROWTH FACTOR 23; FUROSEMIDE; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SERUM ALBUMIN; SEVELAMER;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHRONIC GLOMERULONEPHRITIS; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE ABSORPTION; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE INTAKE; PHOSPHATE METABOLISM; PHOSPHATE URINE LEVEL; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINARY EXCRETION; URINE VOLUME;

AGED; BIOLOGICAL MARKERS; BLOOD UREA NITROGEN; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HOMEOSTASIS; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PARATHYROID HORMONE; PHOSPHATES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84875751680     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12039     Document Type: Article

References (27)

1. Farrow EG, White KE,. Recent advances in renal phosphate handling. Nat. Rev. Nephrol. 2010; 6: 207-217.
2. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R,. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008; 74: 148-157.
3. Toussaint ND, Pedagogos E, Tan SJ, et al. Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk. Nephrology 2012; 17: 433-444.
4. Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010; 5: 2251-2257.
5. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 2005; 16: 520-528.
6. Sullivan C, Sayre SS, Leon JB, et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: A randomized controlled trial. JAMA 2009; 301: 629-635.
7. Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin. J. Soc. Nephrol. 2010; 5: 519-530.
8. O'Shea S, Johnson DW,. Addressing risk factors in chronic kidney disease mineral and bone disorder: Can we influence patient-level outcomes? Nephrology 2009; 14: 416-427.
9. Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin. J. Soc. Nephrol. 2008; 3: 1125-1130.
10. Navaneethan SD, Palmer SC, Craig JC, et al. Benefits and harms of phosphate binders in CKD: A systematic review of randomized controlled trial. Am. J. Kidney Dis. 2009; 54: 619-637.
11. Kovesdy CP, Anderson JE, Kalantar-Zadeh K,. Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease. Clin. Nephrol. 2010; 73: 268-275.
12. Wang AY, Lai KN,. The importance of residual renal function in dialysis patients. Kidney Int. 2006; 69: 1726-1732.
13. Schiffl H, Lang SM, Fischer R,. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol. Dial. Transplant. 2002; 17: 1814-1818.
14. McKane W, Chanda SM, Tattersall JE, Greenwood RN, Farrington K,. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int. 2002; 61: 256-265.
15. Marron B, Remon C, Perez-Fontan M, et al. Benefits of preserving residual renal function in peritoneal dialysis. Kidney Int. 2008; 73: s42-51.
16. Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG,. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephol. Dial. Transplant. 2001; 16: 2207-2213.
17. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for hemodialysis adequacy: Update 2006. Guideline 1. Initiation of dialysis. Am. J. Kidney Dis. 2006; 48 (Suppl 1): s13-16.
18. Milutionvic J, Cutler RE, Hoover P, Meijsen B, Scribner BH,. Measurement of residual glomerular filtration rate in the patient receiving repetitive hemodialysis. Kidney Int. 1975; 8: 185-190.
19. Tsun GN, Johnson DW, Hawley C,. Is it time to revisit residual renal function in hemodialysis? Nephrology 2007; 12: 209-217.
20. Vilar E, Farrington K,. Emerging importance of residual renal function in end-stage renal failure. Sem. Dial. 2011; 24: 487-494.
21. Shemin D, Bostom AG, Laliberty P, et al. Residual renal function and mortality risk in hemodialysis patients. Am. J. Kidney Dis. 2001; 38: 85-90.
22. Slatopolsky E, Robson AM, Elkan I, Bricker NS,. Control of phosphate excretion in uremic man. J. Clin. Invest. 1968; 47: 1865-1874.
23. Bijvoet OLM,. Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate. Clin. Sci. 1969; 37: 23-36.
24. Komaba H, Fukagawa M,. FGF23-parathyroid interaction: Implication in chronic kidney disease. Kidney Int. 2010; 77: 292-298.
25. Viaene L, Bammens B, Meijers BKI, Vanrenterghem Y, Vandershueren D, Evenepoel P,. Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. Nephrol. Dial. Transplant. 2012; 27: 2017-2022.
26. Sampaio MS, Ruzany F, Dorigo MD, Suassuna JHR,. Phosphate mass removal during hemodialysis: A comparison between eKT/V-matched conventional and extended dialysis. Am. J. Nephrol. 2012; 36: 121-126.
27. Penne EM, van der Weerd NC, Grooteman MPC, et al. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2011; 6: 281-289.